Kinaction (masitinib) / AB Science 
Welcome,         Profile    Billing    Logout  
 66 Diseases   14 Trials   14 Trials   518 News 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kinaction (masitinib) / AB Science
2015-000897-36: A study to compare masitinib in combination with irinotecan to placebo in combination with irinotecan in the treatment of patients with esophagogastric adenocarcinoma Κλινική μελέτη για τη σύγκριση της μασιτινίμπης σε συνδυασμό με ιρινοτεκάνη έναντι του συνδυασμού placebo με ιρινοτεκάνη στη θεραπεία ασθενών με οισοφαγογαστρικό αδενοκαρκίνωμα

Ongoing
3
364
Europe
Masitinib, Irinotecan, AB1010, INEOF00997, Film-coated tablet, Concentrate for solution for infusion, IRINOTECAN/DEMO
AB science, AB science
Πatients with advanced-stage esophagogastric adenocarcinoma who have relapsed after first-line chemotherapy Ασθενείς με προχωρημένου σταδίου οισοφαγογαστρικό αδενοκαρκίνωμα οι οποίοι υποτροπίασαν μετά από την πρώτης γραμμής χημειοθεραπεία, Εsophagogastric adenocarcinoma Οισοφαγογαστρικό αδενοκαρκίνωμα, Diseases [C] - Digestive System Diseases [C06]
 
 
2021-002179-21: A phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer's disease treated with standard of care: cholinesterase inhibitors, memantine

Not yet recruiting
3
600
Europe
Masitinib, AB1010, Film-coated tablet
AB Science, ABScience, AB Science, ABScience
Alzheimer's disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT03127267 / 2019-001862-13: Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Recruiting
3
495
Europe, US, RoW
Masitinib (6.0), AB1010, Riluzole, Rilutek, Placebo, Placebo Oral Tablet, Masitinib (4.5)
AB Science
Amyotrophic Lateral Sclerosis
12/23
12/23
NCT04333108 / 2016-001447-39: Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Recruiting
3
140
Europe, RoW
Masitinib, AB1010, Placebo, Best Supportive Care
AB Science
Indolent Systemic Mastocytosis
12/24
06/25
MASIMS, NCT05441488 / 2021-000639-30: Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Recruiting
3
800
Europe, RoW
Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010
AB Science
Progressive Multiple Sclerosis
12/25
12/25
NCT05564169: Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Not yet recruiting
3
600
Europe
Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010, Standard of care
AB Science
Alzheimer Disease
12/26
12/26
2010-021091-28: A clinical study to determine whether a new drug masitinib is safe and effective in cancer of the white blood cells.

Ongoing
2/3
267
Europe, RoW
Masitinib mesylate, Gemcitabine, Dexamethasone, AB1010, Film-coated tablet, Powder for infusion, Tablet, Gemcitabine, Dexamethasone
AB Science, AB Science
Relapsed or refractory peripheral T-cell lymphoma, Cancer of the white blood cells (T-lymphocytes), Diseases [C] - Cancer [C04]
 
 
2012-004222-25: Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's disease

Ongoing
2/3
450
Europe
Masitinib, AB1010, Film-coated tablet
AB Science, AB Science
Crohn's disease, Inflammatory bowel disease, Diseases [C] - Digestive System Diseases [C06]
 
 
2010-022793-14: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masitinib in combination with irinotecan, or masitinib in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol), as second line chemotherapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma.

Not yet recruiting
2
57
Europe
masitinib, Irinotecan, AB1010, Film-coated tablet, Solution for infusion, Irinotecan/Campto®/Camptosar®
AB Science
gastric or gastro-oesophageal junction metastatic adenocarcinoma
 
 
2010-020603-79: Evaluation of masitinib in acute ischemic stroke Evaluación de masitinib en pacientes con ictus isquémico agudo

Ongoing
2
45
Europe
masitinib, AB1010 tablets,
AB Science, ABScience
patients suffering from Acute Ischemic Stroke Pacientes con ictus isquémico agudo
 
 
2012-005586-13: A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) Estudio de fase IIa prospectivo, multicéntrico, randomizado, doble ciego, y controlado con placebo para comparar la eficacia y seguridad del tratamiento con masitinib durante de 24 semanas frente a placebo en pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC)

Ongoing
2
30
Europe
MASITINIB, AB1010,
AB SCIENCE, AB Science, AB SCIENCE, AB Science
Patients with severe COPD Pacientes con EPOC grave
 
 
2021-005406-96: A 24-week study to compare efficacy and safety of oral masitinib to placebo in the treatment of patients with severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment

Ongoing
2
78
Europe
AB1010 Tablets, AB1010 Tablets, Film-coated tablet
AB Science, AB Science
severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment, severe mast cell activation syndrome (MCAS), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04622865 / 2020-001635-27: Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Recruiting
2
200
Europe
Masitinib, AB1010, Isoquercetin, quercetin-3-O-glucoside, isotrifoliin, Best Supportive Care, BSC
AB Science
SARS-CoV 2, COVID-19, Coronavirus Disease 2019
12/23
12/23
NCT05047783: Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Recruiting
2
78
Europe, RoW
Masitinib Mesylate, Masitinib, AB1010, Placebo
AB Science
Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019
12/23
12/23
NCT05449444: Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Recruiting
2
72
Europe, US
Masitinib 4.5 mg/kg/day, AB1010, Placebo, Placebo Oral Tablet, Best supportive care, BSC, Masitinib 6.0 mg/kg/day
AB Science
Mast Cell Activation Syndrome
12/24
12/24
2010-022620-77: Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancer Evaluación de la seguridad y eficacia de masitinib combinada con etopósido o irinotecán en pacientes con cáncer de hígado recurrente

Ongoing
1/2
36
Europe
masitinib, etoposide, irinotecan, AB1010, Film-coated tablet, Solution for infusion, Solution for injection, Toposar®, VePesid®, Etopophos®, Camptosar
AB Science, , AB Science
hepatocellular carcinoma, Hepatic cancer Cáncer de Hígado, Diseases [C] - Cancer [C04]
 
 

Download Options